ÖZLEM FENTOĞLU, FATMA YEŞİM KIRZIOĞLU, MEMDUHA TÖZÜM BULUT, ŞİVGE KURGAN, HAVVA KOÇAK, RECEP SÜTCÜ, BANU KALE KÖROĞLU, MERAL GÜNHAN

Serum Lp-PLA2: as a novel viewpoint in periodontal treatment of hyperlipidaemics

Background/aim: To evaluate the effects of periodontal treatment on serum lipoprotein-associated phospholipase A2 (Lp-PLA2) and C-reactive protein (CRP) levels in hyperlipidaemic patients with periodontitis. Materials and methods: The study included 52 hyperlipidaemics and 28 systemically healthy controls (C) with periodontitis. Of the 52 hyperlipidaemics, 29 received a suggested diet (HD), and 23 of them were prescribed statin (HS). Clinical periodontal parameters, serum lipids, Lp-PLA2, and CRP levels were assessed at the baseline and 2 months after the completion of the nonsurgical periodontal treatment (2MPT). Serum parameters were also evaluated 1 week following the periodontal treatment (1WPT). Results: At the baseline, patients in the HS group had a higher percentage of bleeding on probing than those in the C and HD groups. Hyperlipidaemics had higher serum triglyceride levels than the control group at 2MPT compared to the baseline. At 2MPT, the levels of Lp-PLA2 in the HS group were significantly higher compared to the baseline and 1WPT. There were no statistically significant differences in CRP levels between study periods for all groups. Conclusion: The periodontal treatment may affect the inflammatory control of hyperlipidaemic patients with periodontitis via increased Lp-PLA2 levels and severity of the impaired lipid metabolism. These findings may be important regarding the therapeutic strategies for hyperlipidaemics with periodontitis.

Anahtar Kelimeler:

Periodontal treatment, hyperlipidaemia, periodontitis, lipoprotein-associated phospholipase A2, C-reactive protein

Serum Lp-PLA2: as a novel viewpoint in periodontal treatment of hyperlipidaemics

Keywords:

Periodontal treatment, hyperlipidaemia, periodontitis, lipoprotein-associated phospholipase A2, C-reactive protein,

PDF

___

Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91: 2844–2850.
Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol 1983; 34: 141– 212.
Yang EH, McConnell JP, Lennon RJ, Barsness GW, Pumper G, Hartman SJ, Rihal CS, Lerman LO, Lerman A. Lipoprotein- associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol 2006; 26: 106–111.
Kolodgie FD, Burke AP, Skorija KS, Ladich E, Kutys R, Makuria AT, Virmani R. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006; 26: 2523–2529.
Lösche W, Marshai GJ, Apatzidou DA, Krause S, Kocher T, Kinane DF. Lipoprotein associated phospholipase A2 and plasma lipids in patients with destructive periodontal disease. J Clin Periodontol 2005; 32: 640–644.
Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol 2001; 38:189–197.
Chang MK, Binder CJ, Torzewski M, Witztum JL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. P Natl Acad Sci USA 2002; 99: 13043–13048.
Paraskevas S, Huizinga JD, Loos BG. A systematic review and meta-analyses on C reactive protein in relation to periodontitis. J Clin Periodontol 2008; 35: 277–290.
Noack B, Jachmann I, Roscher S, Sieber L, Kopprasch S, Lück C, Hanefeld M, Hoffmann T. Metabolic diseases and their possible link to risk indicators of periodontitis. J Periodontol 2000; 71: 898–903.
Fentoğlu Ö, Öz G, Taşdelen P, Uskun E, Aykaç Y, Bozkurt FY. Periodontal status in subjects with hyperlipidaemia. J Periodontol 2009; 80: 267–273.
Awartani F, Atassi F. Evaluation of periodontal status in subjects with hyperlipidaemia. J Contemp Dent Pract 2010; 11: 33–40.
Oz SG, Fentoglu O, Kilicarslan A, Guven GS, Tanrover MD, Aykac Y, Sozen T. Beneficial effects of periodontal treatment on metabolic control of hypercholesterolemia. South Med J 2007; 100: 686–691.
Fentoğlu Ö, Sözen T, Öz SG, Kale B, Sönmez Y, Öztürk Tonguç M, Gürgan CA, Aykaç Y, Kırzıoğlu FY. Short-term effects of periodontal therapy as an adjunct to anti-lipaemic treatment. Oral Dis 2010; 16: 648–654.
Fentoğlu Ö, Köroğlu BK, Hiçyılmaz H, Sert T, Özdem M, Sütçü R, Tamer MN, Orhan H, Ay ZY, Öztürk Tonguç M et al. Pro-inflammatory cytokine levels in association between periodontal disease and hyperlipidaemia. J Clin Periodontol 2011; 38: 8–16.
Fentoğlu Ö, Köroğlu BK, Kara Y, Doğan B, Yılmaz G, Sütçü R, Ay ZY, Tonguç MÖ, Orhan H, Tamer MN et al. Serum lipoprotein-associated phospholipase A(2) and C-reactive protein levels in association between periodontal disease and hyperlipidaemia. J Periodontol 2011; 82: 350–359.
Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake, DB, Pasternak RC, Smith SC, Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227–239.
Silness, J, Löe H. Periodontal disease in pregnancy. II. Correlation between oral hygiene and periodontal condition. Acta Odontol Scand 1964; 22: 121–135.
Löe H, Silness J. Periodontal disease in pregnancy. I. Prevalence and severity. Acta Odontol Scand 1963; 21: 533–551.
Armitage GC. Development of a classification system for periodontal diseases and conditions. Ann Periodontol 1999; 4: 1–6.
Takata Y, Ansai T, Matsumura K, Awano S, Hamasaki T, Sonoki K, Kusaba A, Akifusa S, Takehara T. Relationship between tooth loss and electrocardiographic abnormalities in octogenarians. J Dent Res 2001; 80: 1648–1652.
Lawrence HP, Garcia RI, Essick GK, Hawkins R, Krall EA, Spiro A 3rd, Vokonas PS, Kong L, King T, Koch GG. A longitudinal study of the association between tooth loss and age-related hearing loss. Spec Care Dentist 2001; 21: 129–140.
Pussinen PJ, Vilkuna-Rautiainen T, Alfthan G, Palosuo T, Jauhiainen M, Sundvall J, Vesanen M, Mattila K, Asikainen S. Severe periodontitis enhances macrophage activation via increased serum lipopolysaccharide. Arterioscler Thromb Vasc Biol 2004; 24: 2174–2180.
D’Aiuto F, Nibali L, Parkar M, Suvan J, Tonetti MS. Short-term effects of intensive periodontal therapy on serum inflammatory markers and cholesterol. J Dent Res 2005; 84: 269–273.
Gabay C, Kushner I. Acute phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448–454.
Carpentier YA, Scruel O. Changes in the concentration and composition of plasma lipoproteins during the acute phase response. Curr Opin Clin Nutr Metab Care 2002; 5: 153–158.
Pfohl M, Schreiber I, Liebich HM, Häring HU, Hoffmeister HM. Upregulation of cholesterol synthesis after acute myocardial infarction – is cholesterol a positive acute phase reactant? Atherosclerosis 1999; 142: 389–393.
Feingold KR, Staprans I, Memon RA, Moser AH, Shigenaga JK, Doerrler W, Dinarello CA, Grunfeld C. Endotoxin rapidly induces changes in lipid metabolism that produce hypertriglyceridemia: low doses stimulate hepatic triglyceride production while high doses inhibit clearance. J Lipid Res 1992; 33: 1765–1776.
Khovidhunkit W, Memon RA, Feingold KR, Grunfeld C. Infection and inflammation-induced proatherogenic changes of lipoproteins. J Infect Dis 2000; 181: S462–S472.
Lösche W, Karapetow F, Pohl A, Krause S, Kocher T. Plasmalipide und blutglucose sowie PAF-Acetylhydrolase bci marginaler paradontitis. Dtsch Zahnärztl Z 2000; 55: 431–434 (in German).
Khakpour H, Frishman WH. Lipoprotein-associated phospholipase A2: an independent predictor of cardiovascular risk and a novel target for immunomodulation therapy. Cardiol Rev 2009; 17: 222–229.
Quist-Paulsen P. Statins and inflammation: an update. Curr Opin Cardiol 2010; 25: 399–405.
Fentoğlu Ö, Kırzıoğlu FY, Özdem M, Koçak H, Sütçü R, Sert T. Proinflammatory cytokine levels in hyperlipidemic patients with periodontitis after periodontal treatment. Oral Dis 2012; 18: 299–306.
Pruzanski W, Vadas P, Browning J. Secretory non-pancreatic group II phospholipase A2: role in physiologic and inflammatory processes. J Lipid Mediat 1993; 8: 161–167.
Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, Sharrett AR. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004; 109: 837–842.